

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number  
**WO 2005/054201 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 215/227**,  
241/44, 401/06, 403/06, 405/06, 405/14, 407/06, 407/12,  
A61K 31/4704, 31/498, A61P 1/04, 13/12, 19/02, 21/00,  
25/28

(21) International Application Number:  
PCT/EP2004/013163

(22) International Filing Date:  
18 November 2004 (18.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PCT/EP03/13028  
20 November 2003 (20.11.2003) EP  
03078860.8 5 December 2003 (05.12.2003) EP

(71) Applicant (for all designated States except US):  
**JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MABIRE, Do-**  
**minique, Jean-Pierre** [FR/FR]; Janssen-Cilag, Campus  
de Maigremont, F-27100 Val de Reuil (FR). **GUILLE-**  
**MONT, Jérôme, Emile, Georges** [FR/FR]; Janssen-Cilag,  
Campus de Maigremont, F-27100 Val de Reuil (FR). **VAN**  
**DUN, Jacobus, Alphonsus, Josephus** [BE/BE]; Janssen  
Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse  
(BE). **SOMERS, Maria, Victorina, Francisca** [BE/BE];  
Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340  
Beerse (BE). **WOUTERS, Walter, Boudewijn, Leopold**  
[BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30,  
B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEU-**  
**TICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.



(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,  
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI  
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS  
POLY(ADP-RIBOSE) POLYMERASE INHIBITORS



(57) Abstract: The present invention provides compounds of formula (I) and compounds of formula (I), (VII-a), as well as pharma-  
ceutical compositions comprising said compounds and their use as PARP inhibitors wherein n, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>e</sup>, R<sup>d</sup> and  
X have defined meanings.



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*